首頁 > 市場調查報告書 > 製藥

呼吸器

市場調查報告書

商品編碼

1708767

全球鮑氏不動桿菌肺炎治療市場依藥物類別、給藥途徑及地區分類

Global Acinetobacter Pneumonia Therapeutics Market, By Drug Class, By Route of Administration, By Geography

出版日期: 2025年03月04日 | 出版商:

Coherent Market Insights | 英文 132 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計 2025 年全球鮑氏不動桿菌肺炎治療市值為 7.251 億美元，到 2032 年將達到 10.76 億美元。預計 2025 年至 2032 年的年複合成長率(CAGR)為 5.8%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	7.251億美元
效能數據	2020-2024	預測期	2025-2032
預測期間：2025年至2032年的複合年成長率	5.80%	2032年價值預測	10.76億美元

數字。 2025年全球鮑氏不動桿菌肺炎藥物各地區全球市場佔有率（%）

鮑氏不動桿菌肺炎是一種由鮑氏不動桿菌屬細菌引起的一種嚴重肺炎。這些細菌通常存在於土壤和水中。近年來，由多重抗藥性不動鮑氏不動桿菌菌株引起的醫院內肺炎病例急劇增加。它通常影響免疫力缺乏的患者和加護病房接受機械通氣的患者。抗生素抗藥性是鮑氏不動桿菌肺炎治療的一大挑戰。當務之急是針對這種病原體採取新的治療方法。

市場動態

全球鮑氏不動桿菌肺炎治療市場受到抗藥性菌株的傳播以及醫院獲得性肺炎或人工呼吸器相關性肺炎發病率的增加所驅動。根據美國疾病管制與預防中心的數據，鮑氏不動桿菌感染疾病每年占美國美國內獲得性肺炎病例的 8% 至 10%。此外，有限的抗生素管道和缺乏針對鮑氏不動桿菌肺炎的核准治療方法也為該市場創造了機會。然而，高昂的開發成本和新藥認證相關的監管障礙阻礙了市場的成長。市場受到多種因素的影響，例如多重抗藥性菌株的增加、診斷技術的進步以及對有效治療方案的需求。製藥公司、研究機構和醫療保健提供者之間的合作在推進治療方案方面發揮關鍵作用。不斷演變的感染疾病情勢和 COVID-19 大流行的影響凸顯了透過創新治療性介入和公共衛生措施持續努力應對鮑氏不動桿菌肺炎的重要性。

研究的主要特點

本報告對全球鮑氏不動桿菌肺炎治療市場進行了詳細分析，並以 2024 年為基準年，展示了預測期（2025-2032 年）的市場規模和復合年成長率。

它還強調了各個領域的潛在收益成長機會，並說明了該市場的引人注目的投資提案矩陣。

它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的主要考察。

根據公司亮點、產品系列、關鍵亮點、績效和策略等參數，列出了全球鮑氏不動桿菌肺炎治療市場的主要企業。

主要企業包括輝瑞、默克、葛蘭素史克 (GSK)、阿斯特捷利康、諾華、強生、賽諾菲、拜耳、巴塞利亞製藥等。

本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、高階市場策略、市場擴張和行銷策略做出明智的決策。

全球鮑氏不動桿菌肺炎治療藥物市場報告針對該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。

相關人員可以透過全球鮑氏不動桿菌肺炎治療藥物市場分析中使用的各種策略矩陣來促進決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 725.1 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	5.80%	2032 Value Projection:	USD 1,076. Mn

Acinetobacter pneumonia is a severe type of pneumonia caused by the Acinetobacter species of bacteria. These bacteria are commonly found in soil and water. In recent times, there has been a steep rise in the number of cases of hospital-acquired pneumonia caused by multidrug-resistant Acinetobacter strains. Typically, it affects immunocompromised patients or those on mechanical ventilation in intensive care units. Antibiotic resistance has emerged as a major challenge in treating Acinetobacter pneumonia. Novel therapeutic approaches targeting this pathogen are the need of the hour.

Market Dynamics:

The global Acinetobacter pneumonia therapeutics market is driven by the growing prevalence of drug-resistant strains and increasing incidence of hospital-acquired or ventilator-associated pneumonia. According to the Centers for Disease Control and Prevention, Acinetobacter infections account for 8-10% of all hospital-acquired pneumonia cases in the U.S. every year. Moreover, the restricted antibacterial pipeline and lack of approved therapies specific to Acinetobacter pneumonia act as opportunities in the market. However, high development costs and regulatory hurdles associated with new drug approvals hamper the market growth. The market is influenced by factors such as increasing incidence of multidrug-resistant strains, advancements in diagnostic technologies, and the need for effective treatment options. Collaborations between pharmaceutical companies, research institutions, and healthcare providers play a crucial role in advancing therapeutic solutions. The evolving landscape of infectious diseases and the impact of the COVID-19 pandemic underscore the importance of sustained efforts to address Acinetobacter pneumonia through innovative therapeutic interventions and public health measures.

Key Features of the Study:

This report provides an in-depth analysis of the global acinetobacter pneumonia therapeutics market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global acinetobacter pneumonia therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc (GSK), AstraZeneca plc, Novartis AG, Johnson & Johnson, Sanofi S.A., Bayer AG, and Basilea Pharmaceutica

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global acinetobacter pneumonia therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acinetobacter pneumonia therapeutics market.

Detailed Segmentation:

Global Acinetobacter Pneumonia Therapeutics Market, By Drug Class
- Cephalosporins
- Carbapenems
- Aminoglycosides
- Polymyxins
Global Acinetobacter Pneumonia Therapeutics Market, By Route of Administration
- Oral
- Intravenous
- Others
Global Acinetobacter Pneumonia Therapeutics Market, By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles
- Pfizer Inc.
- Merck & Co., Inc.
- GlaxoSmithKline plc (GSK)
- AstraZeneca plc
- Novartis AG
- Johnson & Johnson
- Sanofi S.A.
- Bayer AG
- Basilea Pharmaceutica

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Acinetobacter Pneumonia Therapeutics Market, By Drug Class
- Global Acinetobacter Pneumonia Therapeutics Market, By Route of Administration
- Global Acinetobacter Pneumonia Therapeutics Market, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Rising prevalence of Acinetobacter pneumonia infections
- Increasing research & development activities
- Growing healthcare expenditure
Impact Analysis
Key Highlights
Regulatory Scenario
Service offering Portfolio
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Pipeline Analysis

4. Global Acinetobacter Pneumonia Therapeutics Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Acinetobacter Pneumonia Therapeutics Market, By Drug Class, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Cephalosporins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Carbapenems
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Aminoglycosides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Polymyxins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global Acinetobacter Pneumonia Therapeutics Market, By Route of Administration, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

7. Global Acinetobacter Pneumonia Therapeutics Market, By Region, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Pfizer Inc.
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
Merck & Co., Inc.
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
GlaxoSmithKline plc (GSK)
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
AstraZeneca plc
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
Sanofi S.A.
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
Bayer AG
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
Basilea Pharmaceutica
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
Analyst Views